NASDAQ$RAPT
RAPT Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
RAPT Therapeutics reported Q3 2025 with no product revenue and a net loss of $17.6M ($0.28 per share).
The clinical-stage biotech had no collaboration or product revenue in the quarter while advancing ozureprubart and pipeline programs. Net loss was $17.6 million, or $0.28 per share, as R&D spend continued ahead of potential partnering.
- Pre-revenue quarter focused on ozureprubart development.
- Net loss $17.6M; EPS $(0.28).
- Jeyou license and Hanmi agreements shape global rights.
- Cash runway depends on financing and partnership options.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$0
Forward guidance
The filing discusses RAPT Therapeutics's outlook, capital priorities, and key risks, including guidance or operating targets where disclosed.
Tailwinds
- RAPT Therapeutics cites execution and demand supporting the near-term outlook.
- Balance sheet and capital allocation remain focal points in the filing.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competition, and input costs may pressure margins quarter to quarter.
- One-time items and segment mix can affect comparability versus prior periods.
- Clinical and regulatory timelines drive funding needs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q3 2025
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro